Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: RNA interference-based inflammation therapeutics - Marina Biotech

Drug Profile

Research programme: RNA interference-based inflammation therapeutics - Marina Biotech

Alternative Names: MDR-06155

Latest Information Update: 24 Aug 2010

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Nastech Pharmaceutical Company
  • Developer Marina Biotech
  • Class Small interfering RNA
  • Mechanism of Action Cytokine inhibitors; RNA interference; Tumour necrosis factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Inflammatory bowel diseases; Rheumatoid arthritis

Most Recent Events

  • 22 Jul 2010 Discontinued - Preclinical for Inflammatory bowel disease in USA (Parenteral)
  • 22 Jul 2010 Discontinued - Preclinical for Rheumatoid arthritis in USA (Parenteral)
  • 02 Jul 2010 MDRNA merged with Cequent Pharmaceuticals forming Marina Biotech
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top